

# Katy Milne

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/294751/publications.pdf>

Version: 2024-02-01

43  
papers

5,118  
citations

159585

30  
h-index

265206

42  
g-index

45  
all docs

45  
docs citations

45  
times ranked

9199  
citing authors

#	ARTICLE	IF	CITATIONS
1	Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 160, 520-529.	1.4	10
2	Loss of Parkinson's susceptibility gene LRRK2 promotes carcinogen-induced lung tumorigenesis. <i>Scientific Reports</i> , 2021, 11, 2097.	3.3	22
3	Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	26
4	Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 406-421.	9.4	155
5	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3828.	3.7	19
6	The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers. <i>Gynecologic Oncology</i> , 2020, 158, 167-177.	1.4	20
7	Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer. <i>Oncotarget</i> , 2020, 11, 2092-2105.	1.8	64
8	Hyperspectral cell sociology reveals spatial tumor-immune cell interactions associated with lung cancer recurrence. , 2019, 7, 13.		37
9	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 2537-2548.	7.0	101
10	Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. <i>Nature Medicine</i> , 2019, 25, 89-94.	30.7	413
11	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 569-580.	7.0	79
12	Somatic mutation-associated T follicular helper cell elevation in lung adenocarcinoma. <i>Oncolmmunology</i> , 2018, 7, e1504728.	4.6	14
13	Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study. <i>Oncolmmunology</i> , 2018, 7, e1502905.	4.6	80
14	The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. <i>Nature Communications</i> , 2018, 9, 3049.	12.8	82
15	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018, 173, 1755-1769.e22.	28.9	261
16	P2.01-065 Quantification of Tumor-Immune Cell Spatial Relationships in the Lung Tumor Microenvironment Using Single Cell Profiling. <i>Journal of Thoracic Oncology</i> , 2017, 12, S826-S827.	1.1	2
17	Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 925-934.	7.0	125
18	Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma. <i>BMC Cancer</i> , 2017, 17, 618.	2.6	42

#	ARTICLE	IF	CITATIONS
19	PD-L1 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017, 8, 51641-51651.	1.8	37
20	CD74 and intratumoral immune response in breast cancer. <i>Oncotarget</i> , 2017, 8, 12664-12674.	1.8	115
21	CD103 and Intratumoral Immune Response in Breast Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 6290-6297.	7.0	125
22	Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer. <i>Journal of Histochemistry and Cytochemistry</i> , 2016, 64, 587-600.	2.5	30
23	Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 3005-3015.	7.0	402
24	PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. <i>Gynecologic Oncology</i> , 2016, 141, 293-302.	1.4	261
25	Recurrent genomic rearrangements in primary testicular lymphoma. <i>Journal of Pathology</i> , 2015, 236, 136-141.	4.5	47
26	PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer. <i>Cancer Immunology Research</i> , 2015, 3, 926-935.	3.4	169
27	Location, location, location. <i>Oncolmmunology</i> , 2014, 3, e27668.	4.6	53
28	Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1125-1134.	7.0	144
29	Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 434-444.	7.0	340
30	Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. <i>Journal of Pathology</i> , 2013, 229, 515-524.	4.5	88
31	Tumour-infiltrating FOXP3+ lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. <i>British Journal of Cancer</i> , 2013, 108, 155-162.	6.4	218
32	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012, 25, 740-750.	5.5	151
33	CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27 <sup>hi</sup> Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 3281-3292.	7.0	447
34	Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes. <i>Journal of Translational Medicine</i> , 2012, 10, 33.	4.4	93
35	Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. <i>Breast Cancer Research</i> , 2011, 13, R126.	5.0	315
36	Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR). <i>Breast Cancer: Basic and Clinical Research</i> , 2011, 5, BCBCR.S7344.	1.1	11

#	ARTICLE	IF	CITATIONS
37	Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model. <i>Breast Cancer Research and Treatment</i> , 2010, 121, 753-763.	2.5	9
38	Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 ( $\hat{I}\pm E/\hat{I}^27$ ) Tj ETQq0 0 0 rgt /Overlock 10 Tf	1.4	59
39	Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors. <i>PLoS ONE</i> , 2009, 4, e6412.	2.5	354
40	Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1865-1875.	4.2	9
41	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. <i>PLoS ONE</i> , 2008, 3, e3409.	2.5	37
42	CD8+ T Cells Induce Complete Regression of Advanced Ovarian Cancers by an Interleukin (IL)-2/IL-15â€œDependent Mechanism. <i>Clinical Cancer Research</i> , 2007, 13, 7172-7180.	7.0	19
43	Spontaneous Mammary Tumors Differ Widely in Their Inherent Sensitivity to Adoptively Transferred T Cells. <i>Cancer Research</i> , 2007, 67, 6442-6450.	0.9	30